Trials / Completed
CompletedNCT06361563
Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada
Patients With Upper Gastrointestinal Cancer Enrolled in a Patient Support Program to Receive Nivolumab in the Adjuvant Setting: Real World Data From Canada
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this observational study is to describe the patient, disease and treatment characteristics of eligible participants with upper gastrointestinal cancer treated with adjuvant nivolumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | As per product label |
Timeline
- Start date
- 2023-09-05
- Primary completion
- 2024-01-25
- Completion
- 2024-01-25
- First posted
- 2024-04-12
- Last updated
- 2024-04-12
Locations
1 site across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06361563. Inclusion in this directory is not an endorsement.